Status:
COMPLETED
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
Lead Sponsor:
Savvysherpa, Inc.
Conditions:
Type2 Diabetes
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels. Subjects will...
Eligibility Criteria
Inclusion
- Be diagnosed with type 2 diabetes
- Currently take a DPP4 inhibitor, SGLT2 inhibitor, GLP-1 agonist, and/or basal insulin
- Be able to read and understand English
- Have access to a telephone
- Have a Medicare health plan
Exclusion
- Pregnant
- Blind
- Deaf
- Currently receiving chemotherapy or radiation therapy to treat cancer
- Addicted to any drugs (including alcohol, painkillers, hallucinogens, or others)
- Critically ill
- Diagnosed with or experiencing:
- Kidney disease stages 4 and 5
- End stage renal disease
- Severe liver disease
- Dementia
- Schizophrenia
- Bipolar disorder
- Autism
- An intellectual or learning disability
- Arrhythmias other than atrial fibrillation
- Congestive heart failure
- Has had a:
- Myocardial infarction within the last 6 months
- Stroke within the last 6 months
- Stroke that resulted in significant disability (e.g., unable to write clearly or walk)
Key Trial Info
Start Date :
July 28 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 25 2019
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT03252964
Start Date
July 28 2017
End Date
February 25 2019
Last Update
May 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rogelio Machuca, MD Family Medicine, PLLC
Las Vegas, Nevada, United States, 89104